BioSpace News Archive

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.

Xencor, Inc. announced three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, being held in San Diego, November 1-5, 2023.

BioInvent International announces it will hold two poster presentations on its anti-tumor necrosis factor receptor 2 programs at the Society of Immunotherapy for Cancer 38th Annual Meeting, held November 3-5, 2023, in San Diego, California.

DepYmed, Inc. is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase family of enzymes.

CTL Amedica has secured Electronic Catalog government contract approval from the U.S. Defense Logistics Agency.

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today it has confirmed a pre-submission meeting date with the U.S. Food and Drug Administration (FDA) scheduled for October 25, 2023.

Gritstone bio, Inc. announced that it was awarded a contract by the Biomedical Advanced Research and Development Authority to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA vaccine candidate containing Spike plus other viral targets to protect against COVID-19.